Previous 10 | Next 10 |
First-in-class lysine gingipain inhibitor, atuzaginstat, has the potential to reduce the malignant progression of oral potentially malignant disorders (OPMD) In vitro study results demonstrate that PD-L1 is induced by P. gingivalis and can be blocked by atuzaginstat At...
Because many receptors and factors lead to the onset and early progression of Alzheimer's disease, targeting any one of them only slightly slows down the progression of Alzheimer's in subgroups. Targeting intervening points between receptor overactivation and peroxynitrite formation, ...
Cortexyme (NASDAQ:CRTX) said its drug COR588 was well-tolerated and safe in a single ascending dose (SAD) portion of a phase 1 trial. The company is developing COR588 to treat diseases related to P. gingivalis (a type of bacteria) infection. In the SAD portion, which enrolled 32 people, of th...
COR588 well-tolerated in all dose cohorts Human pharmacokinetics support once daily oral dosing Multiple ascending dose data expected in the second quarter of 2022 Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream ...
Cassava Sciences (SAVA +2.4%) has warned that it may face a clinical hold on its trials for simufilam after the U.S. FDA imposed them this year on two competitors that are also working on Alzheimer's candidates. The notification was tucked away in Cassava's (SAVA +2.7%) 10-K annual report fil...
COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases. COR388, the first-generation lysine gingipain inhibitor, didn't achieve statistical significance in the entire Alzheimer's population, but...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX) on behalf of Cortexyme stockholders. Our investigation concerns wheth...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX) on behalf of Cortexyme stockholders. Our investigation concerns wheth...
BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Cortexyme, Inc. (NASDAQ: CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more about how they might recover tho...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short-squeeze stocks continue to be hot with traders and we’re going over five candidates that investors will want to watch today. Source: Alextype/Shutterstock.com Today’s list of short-squeeze candid...
News, Short Squeeze, Breakout and More Instantly...
New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful ...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus...